Selected research
Industry Growth & Trends
Global Fatty Liver Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Fatty Liver Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Fatty Liver Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Fatty Liver Drugs market include Allergan, Astra Zenca, Conatus, Gilead Sciences, Hepion Pharmaceuticals, Immuron, Intercept Pharmaceuticals, Madrigal and Merk, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Fatty Liver Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Fatty Liver Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Fatty Liver Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Fatty Liver Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Fatty Liver Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Fatty Liver Drugs Market by Company
Allergan
Astra Zenca
Conatus
Gilead Sciences
Hepion Pharmaceuticals
Immuron
Intercept Pharmaceuticals
Madrigal
Merk
Pfizer
Novartis
Takeda
Fatty Liver Drugs Segment by Type
ALD
NAFLD
Fatty Liver Drugs Segment by Application
Hospital
Clinic
Others
Fatty Liver Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Fatty Liver Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Fatty Liver Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Fatty Liver Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Fatty Liver Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- ALD
- NAFLD
Applications
- Hospital
- Clinic
- Others
Companies covered
- Allergan
- Astra Zenca
- Conatus
- Gilead Sciences
- Hepion Pharmaceuticals
- Immuron
- Intercept Pharmaceuticals
- Madrigal
- Merk
- Pfizer
- Novartis
- Takeda
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Fatty Liver Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Fatty Liver Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Fatty Liver Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Fatty Liver Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Fatty Liver Drugs Market Size (2021-2032)
- 1.5.1 North America Fatty Liver Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Fatty Liver Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Fatty Liver Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Fatty Liver Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Fatty Liver Drugs Market Size Growth Rate (2021-2032)
2 Fatty Liver Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 ALD
- 2.1.2 NAFLD
- 2.2 Global Fatty Liver Drugs Market Size by Type
- 2.2.1 Global Fatty Liver Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Fatty Liver Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Fatty Liver Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Fatty Liver Drugs Market Size by Regions
- 2.3.1 North America Fatty Liver Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Fatty Liver Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Fatty Liver Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Fatty Liver Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Fatty Liver Drugs Market Size Breakdown by Type (2021-2026)
3 Fatty Liver Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Hospital
- 3.1.2 Clinic
- 3.1.3 Others
- 3.2 Global Fatty Liver Drugs Market Size by Application
- 3.2.1 Global Fatty Liver Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Fatty Liver Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Fatty Liver Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Fatty Liver Drugs Market Size by Regions
- 3.3.1 North America Fatty Liver Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Fatty Liver Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Fatty Liver Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Fatty Liver Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Fatty Liver Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Fatty Liver Drugs Industry Trends
- 4.2 Fatty Liver Drugs Industry Drivers
- 4.3 Fatty Liver Drugs Industry Opportunities and Challenges
- 4.4 Fatty Liver Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Fatty Liver Drugs Revenue (2021-2026)
- 5.2 Global Fatty Liver Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Fatty Liver Drugs Key Company Headquarters & Area Served
- 5.4 Global Fatty Liver Drugs Company, Product Type & Application
- 5.5 Global Fatty Liver Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Fatty Liver Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Fatty Liver Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Fatty Liver Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Allergan
- 6.1.1 Allergan Company Information
- 6.1.2 Allergan Business Overview
- 6.1.3 Allergan Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Allergan Fatty Liver Drugs Product Portfolio
- 6.1.5 Allergan Recent Developments
- 6.2 Astra Zenca
- 6.2.1 Astra Zenca Company Information
- 6.2.2 Astra Zenca Business Overview
- 6.2.3 Astra Zenca Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Astra Zenca Fatty Liver Drugs Product Portfolio
- 6.2.5 Astra Zenca Recent Developments
- 6.3 Conatus
- 6.3.1 Conatus Company Information
- 6.3.2 Conatus Business Overview
- 6.3.3 Conatus Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Conatus Fatty Liver Drugs Product Portfolio
- 6.3.5 Conatus Recent Developments
- 6.4 Gilead Sciences
- 6.4.1 Gilead Sciences Company Information
- 6.4.2 Gilead Sciences Business Overview
- 6.4.3 Gilead Sciences Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Gilead Sciences Fatty Liver Drugs Product Portfolio
- 6.4.5 Gilead Sciences Recent Developments
- 6.5 Hepion Pharmaceuticals
- 6.5.1 Hepion Pharmaceuticals Company Information
- 6.5.2 Hepion Pharmaceuticals Business Overview
- 6.5.3 Hepion Pharmaceuticals Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Hepion Pharmaceuticals Fatty Liver Drugs Product Portfolio
- 6.5.5 Hepion Pharmaceuticals Recent Developments
- 6.6 Immuron
- 6.6.1 Immuron Company Information
- 6.6.2 Immuron Business Overview
- 6.6.3 Immuron Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Immuron Fatty Liver Drugs Product Portfolio
- 6.6.5 Immuron Recent Developments
- 6.7 Intercept Pharmaceuticals
- 6.7.1 Intercept Pharmaceuticals Company Information
- 6.7.2 Intercept Pharmaceuticals Business Overview
- 6.7.3 Intercept Pharmaceuticals Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Intercept Pharmaceuticals Fatty Liver Drugs Product Portfolio
- 6.7.5 Intercept Pharmaceuticals Recent Developments
- 6.8 Madrigal
- 6.8.1 Madrigal Company Information
- 6.8.2 Madrigal Business Overview
- 6.8.3 Madrigal Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Madrigal Fatty Liver Drugs Product Portfolio
- 6.8.5 Madrigal Recent Developments
- 6.9 Merk
- 6.9.1 Merk Company Information
- 6.9.2 Merk Business Overview
- 6.9.3 Merk Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Merk Fatty Liver Drugs Product Portfolio
- 6.9.5 Merk Recent Developments
- 6.10 Pfizer
- 6.10.1 Pfizer Company Information
- 6.10.2 Pfizer Business Overview
- 6.10.3 Pfizer Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Pfizer Fatty Liver Drugs Product Portfolio
- 6.10.5 Pfizer Recent Developments
- 6.11 Novartis
- 6.11.1 Novartis Company Information
- 6.11.2 Novartis Business Overview
- 6.11.3 Novartis Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Novartis Fatty Liver Drugs Product Portfolio
- 6.11.5 Novartis Recent Developments
- 6.12 Takeda
- 6.12.1 Takeda Company Information
- 6.12.2 Takeda Business Overview
- 6.12.3 Takeda Fatty Liver Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Takeda Fatty Liver Drugs Product Portfolio
- 6.12.5 Takeda Recent Developments
7 North America
- 7.1 North America Fatty Liver Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Fatty Liver Drugs Market Size by Country (2021-2026)
- 7.3 North America Fatty Liver Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Fatty Liver Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Fatty Liver Drugs Market Size by Country (2021-2026)
- 8.3 Europe Fatty Liver Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Fatty Liver Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Fatty Liver Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Fatty Liver Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Fatty Liver Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Fatty Liver Drugs Market Size by Country (2021-2026)
- 10.3 South America Fatty Liver Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Fatty Liver Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Fatty Liver Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Fatty Liver Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst